Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2026-05-05 19:47:10 ET · period of report 2026-05-01 · accession 0001193125-26-207096 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-05 19:47 | 2026-05-01 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $5.20 | +27.0K | 142.7K | +23% | +$140.4K |
| DMT | 2026-05-05 19:47 | 2026-05-01 | TNGX | Crystal Adam | Pres, R, D | S - Sale+OE | $21.23 | -27.0K | 115.7K | -19% | -$573.1K |
| DT | 2026-05-05 19:47 | 2026-05-01 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $0.00 | -27.0K | 368.0K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | M | A | 27,000 | $5.20 | 142,743 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F2) Includes 3,121 shares that were acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 2 | Common | Common Stock | 2026-05-01 | S | D | 25,900 | $21.19 | 116,843 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F3) Represents the weighted average sales price per share. The shares sold at prices ranging from $20.79 to $21.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Common | Common Stock | 2026-05-01 | S | D | 1,100 | $22.00 | 115,743 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F4) Represents the weighted average sales price per share. The shares sold at prices ranging from $21.80 to $22.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-05-01 | M | D | 27,000 | $0.00 | 368,040 | D | $5.20 · — to 2033-03-01 | 27,000 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F5) This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |